Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?

AUTOR(ES)

Hanauer, Stephen B

FONTE

BMJ Group

RESUMO

Since the introduction of infliximab to treat Crohn's disease, combination therapy with immunosuppressants has reduced immunogenicity, without impacting efficacy. The availability of novel anti‐TNF agents and potential combined toxicities question the risk/benefit of combination therapies.

Documentos Relacionados

• Risks and benefits of biologic therapy for inflammatory bowel diseases
• Worth the Risk? Relationship of Incentives to Risk and Benefit Perceptions and Willingness to Participate in Schizophrenia Research
• True or false coral snake: is it worth the risk? A Micrurus corallinus case report
• INCIDENCE OF INFLAMMATORY BOWEL DISEASE: A SINGLE CENTRE RETROSPECTIVE STUDY
• Inflammatory bowel disease: reviewing an old study under a new perspective